The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri® PharmacoEconomics (TyPE) Study
| Autor: | C Gasperini, L Santoni, R Capra, GB Zimatore, S Fantaccini, Federico Spandonaro, Barbara Polistena |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
lcsh:Medical technology Activities of daily living Cost effectiveness multiple sclerosis Settore SECS-P/06 - Economia Applicata quality-adjusted life year Pharmacoeconomics Natalizumab Quality of life (healthcare) Medicine Intensive care medicine cost-utility cost-effectiveness business.industry Health Policy Multiple sclerosis Societal impact of nanotechnology societal impact medicine.disease Quality-adjusted life year lcsh:R855-855.5 quality of life Natalizumab cost-utility cost-effectiveness societal impact quality-adjusted life year quality of life multiple sclerosis business medicine.drug |
| Zdroj: | Global & Regional Health Technology Assessment, Vol 2019 (2019) |
| Popis: | Multiple sclerosis progressively impairs patients’ ability to independently perform activities of daily living, reduces working capacity, and negatively affects social interactions and relationships, imposing a cost for the society. The aim of this study was to explore the impact on society of treatment of multiple sclerosis with natalizumab in Italian clinical practice. A prospective, observational study was conducted in 24 specialized centers throughout Italy. Direct and indirect costs, as well as the health-related quality of life of patients undergoing treatments, were estimated, while societal impacts were determined using a cost-utility approach. Non-medical direct and indirect costs accounted for 55.7% of the total cost prior to treatment and up to 47.5% after treatment with natalizumab. From the social perspective, greater medical direct costs for second-line drug treatment are nearly offset by savings on non-medical direct costs and by greater productivity, resulting in a +0.5% incremental cost. Assuming a societal perspective, the first year of treatment with natalizumab in real-world clinical practice results in an incremental cost of €2814.8/quality-adjusted life year gained. Multiple sclerosis imposes a considerable burden on patients, their families, and caregivers, stressing the importance of considering the societal perspective in the appraisal process. Treatment with natalizumab shows a noteworthy benefit in social terms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|